Abstract
The combination of immunotherapy and chemotherapy is regarded as a promising approach for the treatment of certain types of cancer. However, the underlying mechanisms need to be fully investigated to guide the design of more efficient protocols for cancer chemoimmunotherapy. It is well known that danger-associated molecular patterns (DAMPs) can activate immune cells, including dendritic cells (DCs), via Toll-like receptors (TLRs); however, the role of DAMPs released from chemical drug-treated tumor cells in the activation of the immune response needs to be further elucidated. Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70). After OXA/5-Fu therapy, the sera of CRC patients also exhibited increased levels of HMGB1 and HSP70, both of which are well-known DAMPs. The supernatants of dying CRC cells treated with OXA/5-Fu promoted mouse and human DC maturation, with upregulation of HLA-DR, CD80 and CD86 expression and enhancement of IL-1β, TNF-α, MIP-1α, MIP-1β, RANTES and IP-10 production. Vaccines composed of DCs pulsed with the supernatants of chemically stressed CRC cells induced a more significant IFN-γ-producing Th1 response both in vitro and in vivo. However, the supernatants of chemically stressed CRC cells failed to induce phenotypic maturation and cytokine production in TLR4-deficient DCs, indicating an essential role of TLR4 in DAMP-induced DC maturation and activation. Furthermore, pulsing with the supernatants of chemically stressed CRC cells did not efficiently induce an IFN-γ-producing Th1 response in TLR4-deficient DCs. Collectively, these results demonstrate that DAMPs released from chemically stressed cancer cells can activate DCs via TLR4 and enhance the induction of an anti-tumor T-cell immune response, delineating a clinically relevant immuno-adjuvant pathway triggered by DAMPs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25: 1247–1254.
Landry JC, Feng Y, Cohen SJ, Staley CA 3rd, Whittington R, Sigurdson ER et al. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer 2013; 119: 1521–1527.
Nace G, Evankovich J, Eid R, Tsung A . Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun 2012; 4: 6–15.
Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P . Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860–875.
Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013; 133: 624–636.
Krysko O, Løve Aaes T, Bachert C, Vandenabeele P, Krysko DV . Many faces of DAMPs in cancer therapy. Cell Death Dis 2013; 4: 628–631.
He Y, Zha J, Wang Y, Liu W, Yang X, Yu P . Tissue damage-associated “danger signals” influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res 2013; 73: 629–639.
Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012; 72: 3290–3301.
Fu Q, Wu Y, Yan F, Wang N, Wang W, Cao X et al. Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a HSP70L1-Her2(341–456) fusion protein. Cell Mol Immunol 2011; 8: 424–432.
Hee Lee J, Park MS, Hwang JE, Cho SH, Bae WK, Shim HJ et al. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K. Cell Mol Immunol 2013; 10: 275–282.
Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265–277.
Ju DW, Tao Q, Lou G, Bai M, He L, Yang Y et al. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell–tumor cell conjugates. Cancer Res 2001; 61: 3735–3740.
Zhang LH, Pan JP, Yao HP, Sun WJ, Xia DJ, Wang QQ et al. Intrasplenic transplantation of IL-18 gene-modified hepatocytes: an effective approach to reverse hepatic fibrosis in schistosomiasis through induction of dominant Th1 response. Gene Ther 2001; 8: 1333–1342.
Shurin GV, Ma Y, Shurin MR . Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron 2013; 6: 159–167.
Demoulin S, Herfs M, Delvenne P, Hubert P . Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol 2013; 93: 343–352.
Fang H, Wu Y, Huang X, Wang W, Ang B, Cao X et al. Toll-like receptor 4 (TLR4) is essential for HSP70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response. J Biol Chem 2011; 286: 30393–30400.
Thuringer D, Hammann A, Benikhlef N, Fourmaux E, Bouchot A, Wettstein G et al. Transactivation of the epidermal growth factor receptor by heat shock protein 90 via Toll-like receptor 4 contributes to the migration of glioblastoma cells. J Biol Chem 2011; 286: 3418–3428.
Gong J, Zhu B, Murshid A, Adachi H, Song B, Lee A et al. T cell activation by heat shock protein 70 vaccine requires TLR signaling and scavenger receptor expressed by endothelial cells-1. J Immunol 2009; 183: 3092–3098.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050–1059.
Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010; 16: 413–419.
Gasse P, Riteau N, Charron S, Girre S, Fick L, Pétrilli V et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009; 179: 903–913.
Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology 2012; 1: 271–278.
Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749–3752.
Wan T, Zhou X, Chen G, An H, Chen T, Zhang W et al. Novel heat shock protein HSP70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant. Blood 2004; 103: 1747–1754.
Liu X, Zhan Z, Li D, Xu L, Ma F, Zhang P et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 2011; 12: 416–424.
Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189: 1777–1782.
Fredly H, Ersvær E, Gjertsen BT, Bruserud O . Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 2011; 25: 1549–1556.
Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol 2013; 133: 1610–1619.
Tongu M, Harashima N, Yamada T, Harada T, Harada M . Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother 2010; 59: 769–777.
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59–73.
Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 2013; 19: 28–33.
Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P et al. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer 2013; 132: 2349–2358.
Date K, Hall J, Greenman J, Maraveyas A, Madden LA . Tumour and microparticle tissue factor expression and cancer thrombosis. Thromb Res 2013; 131: 109–115.
Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun 2012; 3: 1282.
Guo Z, Zhang M, Tang H, Cao X . Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. Blood 2005; 106: 2033–2041.
Guo J, Zhang M, Wang B, Yuan Z, Guo Z, Chen T et al. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 2003; 103: 212–220.
Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E et al. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 2002; 9: 793–803.
Li DY, Gu C, Min J, Chu ZH, Ou QJ . Maturation induction of human peripheral blood mononuclear cell-derived dendritic cells. Exp Ther Med 2012; 4: 131–134.
Zhang L, Mi J, Yu Y, Yao H, Chen H, Li M et al. IFN-gamma gene therapy by intrasplenic hepatocyte transplantation: a novel strategy for reversing hepatic fibrosis in Schistosoma japonicum-infected mice. Parasite Immunol 2001; 23: 11–17.
Wu Y, Wan T, Zhou X, Wang B, Yang F, Li N et al. HSP70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine. Cancer Res 2005; 65: 4947–4954.
Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Häcker H et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276: 31332–31339.
Asea A . Heat shock proteins and toll-like receptors. Handb Exp Pharmacol 2008; 183: 111–127.
Todorova J, Pasheva E . High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncol Lett 2012; 3: 214–218.
Rouhiainen A, Kuja-Panula J, Tumova S, Rauvala H . RAGE-mediated cell signaling. Methods Mol Biol 2013; 963: 239–263.
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (81273332, 81101657 and 81123006) and the National High Technology Research, Development Program of China (2012AA020902).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
All authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Fang, H., Ang, B., Xu, X. et al. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell Mol Immunol 11, 150–159 (2014). https://doi.org/10.1038/cmi.2013.59
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2013.59
Keywords
This article is cited by
-
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study
BMC Cancer (2023)
-
Ghost messages: cell death signals spread
Cell Communication and Signaling (2023)
-
Role of dendritic cells in MYD88-mediated immune recognition and osteoinduction initiated by the implantation of biomaterials
International Journal of Oral Science (2023)
-
Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis
Journal of Cancer Research and Clinical Oncology (2023)
-
HMGB1/TLR4 signaling pathway enhances abdominal aortic aneurysm progression in mice by upregulating necroptosis
Inflammation Research (2023)